Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led to “excessive mortality.” ...

Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699 ...

Despite the recent rise in herbal supplement use, research suggests certain supplements may pose risks for patients with ...

Scientists explore how the immune and nervous systems constantly communicate, influencing brain diseases, behavior, and ...

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable ...